FDA Approves TFX's ISO-Gard Mask

Zacks

Recently, Teleflex Incorporated (TFX) obtained regulatory clearance from the U.S. Food & Drug Administration (:FDA) for its ISO-Gard Mask with ClearAir Technology. This new product will form a part of the anesthesia and respiratory business unit and will help reduce exposure of clinicians to dangerous waste anesthetic gases.

In the U.S., almost 20 million surgeries utilize anesthetic gases. As a result, patients recovering in Post Anesthesia Care Unit (:PACU), breathe out these gases that prove to be harmful for nurses and the work environment. The ISO-Gard Mask will lessen the waste anesthetic gas (WAG) providing minimal exposure to the harmful gases in the PACU. According to the Occupational Safety and Health Administration (:OSHA), WAG exposure can cause dizziness, fatigue, headache, and nausea.

This un-patented ClearAir technology is multi-purpose, and not only diminishes the amount of waste air in the hospital environment but provides oxygen to the patient as well. The ISO-Gard Mask with ClearAir technology will expand the Telefelx line of Hudson RCI respiratory products.


Teleflex is a global leader in medical devices used in critical care and surgery. The company focuses on profitable and consistent growth and expects its sales growth to surpass market growth in the long run. It also plans to gain market share in key product areas. Teleflex operates in a highly competitive medical devices industry and stringent regulatory environment. The demand for its products is susceptible to healthcare reimbursement systems in the domestic as well as the international market.

Currently, Teleflex carries a Zacks Rank #2 (Buy). Other medical instrument stocks worth considering are Cyberonics Inc. (CYBX), Given Imaging Ltd. (GIVN) and Cepheid (CPHD), all of which carry a Zacks rank #1 (Strong Buy).

Read the Full Research Report on CPHD

Read the Full Research Report on CYBX

Read the Full Research Report on TFX

Read the Full Research Report on GIVN

Zacks Investment Research



More From Zacks.com
View Comments (0)